Business
Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health
A NovoCare® Recognized Care Provider, Weight Watchers’ new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results
About this update from Ww International, Inc.
[{"type":"text","content":"A NovoCare® Recognized Care Provider, Weight Watchers’ new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone\nNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly FDA approved oral formulation of Wegovy® through its integrated GLP-1 platform. The addition of a once-daily Wegovy pill expands access to GLP-1 treatment and reinforces Weight Watchers’ leadership in delivering comprehensive care models that help people succeed on medication in real life by pairing medical therapy with evidence-based behavior change and ongoing support. Weight Watchers, through its affiliated Weight Watchers Clinic, is a NovoCare® Recognized Care Provider based on its demonstrated ability to deliver FDA-approved GLP-1 medications alongside expert clinical care. Through Weight Watchers Med+ and the GLP-1 Success Program, the company delivers differentiated real-world outcomes by combining access to board-certified physicians and clinicians, evidence-based behavioral science, coaching and community support, and purpose-built digital tools. Together this integrated care model helps members stay engaged, manage side effects, and achieve meaningfully better results than medication alone.“The next era of weight health isn’t about access to medication alone, it’s about helping people succeed on it,” said Tara Comonte, CEO of Weight Watchers. “For decades, Weight Watchers has shown that support drives results and we’re seeing that same truth play out in the GLP-1 era. By pairing access to GLP-1 medications with our proven guidance, structure, and community support, we’re helping people achieve far greater results. Expanding access to Wegovy® pill, a long-anticipated alternative to injectable GLP-1s, is an exciting next step.” Through its integrated platform, Weight Watchers supports people using GLP-1 therapy, with structured behavioral programs designed to improve outcomes—whether medication is prescribed through Weight Watchers Med+ or elsewhere. Weight Watchers’ integrated model has demonstrated meaningful real-world outcomes. At one month, Weight Watchers Med+ members prescribed a GLP-1 who regularly engaged with the GLP-1 Success Program lost ...